Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples